Published in Oncogene on June 26, 2006
WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 6.64
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet (2012) 4.84
The H19 non-coding RNA is essential for human tumor growth. PLoS One (2007) 3.75
Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer (2008) 3.16
Self-renewing diploid Axin2(+) cells fuel homeostatic renewal of the liver. Nature (2015) 2.77
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. Hepatology (2010) 2.31
Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med (2010) 1.84
Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol (2009) 1.79
Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med (2011) 1.74
Transformed Drosophila cells evade diet-mediated insulin resistance through wingless signaling. Cell (2013) 1.69
Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer (2008) 1.59
Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol (2008) 1.56
Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling. PLoS One (2014) 1.52
Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer (2009) 1.44
Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology (2009) 1.31
Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology (2010) 1.26
Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J Gastroenterol (2008) 1.25
Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J Hepatol (2008) 1.25
Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent) (2008) 1.20
EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol (2014) 1.16
Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease. Int J Biol Sci (2010) 1.14
Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci (2011) 1.08
Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma. BMC Cancer (2008) 1.06
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res (2009) 1.04
Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol (2012) 1.00
WNT signaling: an emerging mediator of cancer cell metabolism? Mol Cell Biol (2014) 0.99
Methylation of Dickkopf-3 as a prognostic factor in cirrhosis-related hepatocellular carcinoma. World J Gastroenterol (2010) 0.99
Unique impact of RB loss on hepatic proliferation: tumorigenic stresses uncover distinct pathways of cell cycle control. J Biol Chem (2009) 0.97
PTEN in liver diseases and cancer. World J Gastroenterol (2010) 0.97
Therapeutics Based on microRNA: A New Approach for Liver Cancer. Curr Genomics (2010) 0.96
A cryptic frizzled module in cell surface collagen 18 inhibits Wnt/beta-catenin signaling. PLoS One (2008) 0.96
p53 gene in treatment of hepatic carcinoma: status quo. World J Gastroenterol (2007) 0.95
RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1. Oncogene (2009) 0.95
Zinc-induced Dnmt1 expression involves antagonism between MTF-1 and nuclear receptor SHP. Nucleic Acids Res (2012) 0.94
Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol (2010) 0.94
Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci (2014) 0.89
The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs (2009) 0.88
Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol (2016) 0.88
The oncoprotein p28GANK establishes a positive feedback loop in β-catenin signaling. Cell Res (2011) 0.88
Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol (2012) 0.87
TGF-β signal shifting between tumor suppression and fibro-carcinogenesis in human chronic liver diseases. J Gastroenterol (2013) 0.86
Deficiency of G1 regulators P53, P21Cip1 and/or pRb decreases hepatocyte sensitivity to TGFbeta cell cycle arrest. BMC Cancer (2007) 0.85
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget (2015) 0.85
A novel potent tumour promoter aberrantly overexpressed in most human cancers. Sci Rep (2011) 0.85
Involvement of DNA damage response pathways in hepatocellular carcinoma. Biomed Res Int (2014) 0.84
Genetic alterations in hepatocellular carcinoma: An update. World J Gastroenterol (2016) 0.83
Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma. J Histochem Cytochem (2013) 0.83
Molecular signalling in hepatocellular carcinoma: Role of and crosstalk among WNT/ß-catenin, Sonic Hedgehog, Notch and Dickkopf-1. Can J Gastroenterol Hepatol (2015) 0.82
Klotho: a tumor suppressor and modulator of the Wnt/β-catenin pathway in human hepatocellular carcinoma. Lab Invest (2015) 0.82
Hepatocellular adenoma containing hepatocellular carcinoma in a male patient with familial adenomatous polyposis coli: Report of a case. Surg Today (2011) 0.82
Clonality and allelotype analyses of focal nodular hyperplasia compared with hepatocellular adenoma and carcinoma. World J Gastroenterol (2009) 0.81
TIMP3 controls cell fate to confer hepatocellular carcinoma resistance. Oncogene (2014) 0.81
Apc and p53 interaction in DNA damage and genomic instability in hepatocytes. Oncogene (2014) 0.81
New insights in hepatocellular carcinoma: from bench to bedside. Ann Transl Med (2013) 0.80
Whole-exome sequencing identifies mutated PCK2 and HUWE1 associated with carcinoma cell proliferation in a hepatocellular carcinoma patient. Oncol Lett (2012) 0.80
Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence. World J Gastroenterol (2009) 0.80
Transcript profiling identifies iqgap2(-/-) mouse as a model for advanced human hepatocellular carcinoma. PLoS One (2013) 0.79
Functional interactions between retinoblastoma and c-MYC in a mouse model of hepatocellular carcinoma. PLoS One (2011) 0.79
Correlation analysis of liver tumor-associated genes with liver regeneration. World J Gastroenterol (2007) 0.79
Genome-wide differences in hepatitis C- vs alcoholism-associated hepatocellular carcinoma. World J Gastroenterol (2008) 0.79
RB tumor suppressive function in response to xenobiotic hepatocarcinogens. Am J Pathol (2014) 0.79
Altered {beta}-catenin accumulation in hepatocellular carcinomas of diethylnitrosamine-exposed rhesus macaques. Toxicol Pathol (2008) 0.78
Activating CAR and β-catenin induces uncontrolled liver growth and tumorigenesis. Nat Commun (2015) 0.78
Cancer biology: a new RING to Wnt signaling. Curr Biol (2012) 0.78
Correlation of exon 3 β-catenin mutations with glutamine synthetase staining patterns in hepatocellular adenoma and hepatocellular carcinoma. Mod Pathol (2016) 0.77
Inhibin/activin expression in human and rodent liver: subunits α and βB as new players in human hepatocellular carcinoma? Br J Cancer (2011) 0.77
Activation of signal transduction pathways during hepatic oncogenesis. Cancer Lett (2015) 0.77
Systematic analyses and comprehensive field synopsis of genetic association studies in hepatocellular carcinoma. Oncotarget (2016) 0.77
E2f8 mediates tumor suppression in postnatal liver development. J Clin Invest (2016) 0.77
Research progress in the radioprotective effect of the canonical Wnt pathway. Cancer Biol Med (2013) 0.77
TP53 R72P polymorphism modulates DNA methylation in hepatocellular carcinoma. Mol Cancer (2015) 0.76
β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma. Mol Clin Oncol (2015) 0.76
Zebrafish as a disease model for studying human hepatocellular carcinoma. World J Gastroenterol (2015) 0.76
Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription ofCDKN1A686. Oncotarget (2016) 0.76
Cyclophilin J is a novel peptidyl-prolyl isomerase and target for repressing the growth of hepatocellular carcinoma. PLoS One (2015) 0.76
Wnt-/-β-catenin pathway signaling in human hepatocellular carcinoma. World J Hepatol (2015) 0.75
Hepatoepigenetic Alterations in Viral and Nonviral-Induced Hepatocellular Carcinoma. Biomed Res Int (2016) 0.75
Ganetespib radiosensitization for liver cancer therapy. Cancer Biol Ther (2016) 0.75
Effect of in vivo administration of reprogramming factors in the mouse liver. Oncol Lett (2013) 0.75
Transcriptional regulation of the tumor suppressor FHL2 by p53 in human kidney and liver cells. PLoS One (2014) 0.75
Value of the 8-oxodG/dG ratio in chronic liver inflammation of patients with hepatocellular carcinoma. Redox Biol (2016) 0.75
Regenerating the liver: not so simple after all? F1000Res (2016) 0.75
Role of microRNAs in inflammation-associated liver cancer. Cancer Biol Med (2016) 0.75
Altered expression of AT-rich interactive domain 1A in hepatocellular carcinoma. Int J Clin Exp Pathol (2015) 0.75
Blocking Wnt Secretion Reduces Growth of Hepatocellular Carcinoma Cell Lines Mostly Independent of β-Catenin Signaling. Neoplasia (2016) 0.75
Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model. World J Gastroenterol (2016) 0.75
ChARM: Discovery of combinatorial chromatin modification patterns in hepatitis B virus X-transformed mouse liver cancer using association rule mining. BMC Bioinformatics (2016) 0.75
Cell division cycle 34 is highly expressed in hepatitis C virus-positive hepatocellular carcinoma with favorable phenotypes. Biomed Rep (2017) 0.75
Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology (2001) 2.73
Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol (2010) 2.11
High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum Mol Genet (2001) 1.79
[Benign liver cell tumors: recent results, from molecular biology to diagnosis]. Gastroenterol Clin Biol (2008) 1.37
Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol (2007) 1.33
Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene (1999) 1.22
LINE-I element insertion at the t(11;22) translocation breakpoint of a desmoplastic small round cell tumor. Genes Chromosomes Cancer (1997) 1.14
Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer (2013) 1.06
Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma. Oncogene (2001) 0.95
Inflammatory syndrome with liver adenomatosis: the beneficial effects of surgical management. Gut (2007) 0.90
[Semi-automated quantitative method for detecting the loss of heterozygosity at the long arm of chromosome 4 in hepatocellular carcinoma]. Gastroenterol Clin Biol (1999) 0.90
Molecular characterization of germline NF2 gene rearrangements. Genomics (2000) 0.86
Focal nodular hyperplasia, hepatocellular adenomas: past, present, future. Gastroenterol Clin Biol (2010) 0.85
Characterisation of 16 polymorphic markers in the NF2 gene: application to hemizygosity detection. Hum Mutat (1999) 0.84
NF2 gene deletion in a family with a mild phenotype. J Med Genet (2000) 0.81
Composite exon structure of an unusual Ig lambda-like gene located at human 22q11 position. Mamm Genome (1996) 0.79
PCR-based genotyping can generate artifacts in LOH analyses. Biotechniques (1999) 0.78
Cryptic exons as a source of increased diversity of Ewing tumor-associated EWS-FLI1 chimeric products. Genomics (1999) 0.76
[Genetic alterations in hepatocellular carcinomas: associations with clinical parameters]. Gastroenterol Clin Biol (2001) 0.75
[Genetic alterations in hepatocellular adenomas]. Pathol Biol (Paris) (2004) 0.75